Name: DiabetOmics Financials 2026 – Revenue, P&L & Cash Flow
Creator: Inc42 Datalabs

Acquisition highlights of DiabetOmics and a snapshot of its key metrics.

Founded in 2008, DiabetOmics operates in Health Tech industry. Initially focusing on affordable, non-invasive tests for diabetes and its complications, the company has expanded its portfolio to include a range of biomarkers for comprehensive diabetes care. DiabetOmics announced a significant development with its non-invasive testing technology gaining further traction through expanded clinical validation studies. The company has enhanced its reach by launching additional diagnostic tools targeting gestational diabetes and prediabetes. Competing with companies such as GOQii and Inito.

Charles Roberts

Paturi V. Rao

Srinivasa Nagalla

Funding highlights of DiabetOmics and a snapshot of its key metrics.

Rogue Venture Partners

VenturEast

Investment highlights of DiabetOmics and a snapshot of its key metrics.

DiabetOmics reported ₹7.8 Cr revenue in FY24 with a profit of ₹1.7 Cr. Explore P&L, balance sheet and cash flow on Inc42 Datalabs.

DiabetOmics Financials 2026 – Revenue, P&L & Cash Flow

DiabetOmics

A snapshot of highlights, scale, and metrics

An overview of key people in DiabetOmics.

A Health Tech Funded Company Based Out Of Hyderabad

Decoding financial health metrics of DiabetOmics

DiabetOmics - Financials, Revenue, P&L Statement, Balance Sheet, Cash Flow & More

DiabetOmics: Financial Breakdown

Disclaimer